Stockscreener 앱 받기
2.30
0.00%
0.00
시간 외 거래:
2.28
-0.02
-0.87%
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - Investing.com Australia
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Sahm
Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com
Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech
Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN
Ovid Therapeutics raises $60M, expands epilepsy drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com Canada
Ovid Therapeutics: Advancing Small Molecule Medicines for Epilepsy and Psychiatric Disorders – Pipeline, Strategy, and Company Overview - Minichart
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative - simplywall.st
Earnings Call Summary | Ovid Therapeutics(OVID.US) Q4 2025 Earnings Conference - 富途牛牛
Ovid Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Ovid Therapeutics Q4 Earnings Call Highlights - MarketBeat
Ovid Therapeutics 2025 10-K: $7.3M Revenue, $(17.41)M Net Loss - TradingView
OVID: 2025 saw higher revenue, reduced losses, and strong cash to support advancing CNS drug programs - TradingView
[10-K] Ovid Therapeutics Inc. Files Annual Report | OVID SEC FilingForm 10-K - Stock Titan
Ovid Therapeutics (OVID) Reports Strong Q4 Revenue and Expands C - GuruFocus
Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 - AlphaStreet
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Globe and Mail
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Ovid Therapeutics Expands OV329 Epilepsy Program, Launches Phase 1 OV4071 Trial, and Reports Strong 2025 Financial Results - Minichart
Ovid Therapeutics Faces Market Uncertainty Amid Recent Earnings Review - StocksToTrade
Earnings call transcript: Ovid Therapeutics Q4 2025 Surprises with Earnings Beat - Investing.com
OVID’s Latest Strategic Moves Propel Stock Price Surge - timothysykes.com
Ovid Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors - marketscreener.com
Ovid Therapeutics (OVID) Q4 Results Exceed Expectations for Earnings and Revenue - Bitget
Ovid (OVID) Reports Strong Cash Position as of Year-End 2025 - GuruFocus
Ovid Raises $60 Million in PIPE at $2.01, Including Pre-Funded Warrants - TradingView
Ovid Therapeutics (NASDAQ:OVID) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline - TipRanks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics raises $60M, expands epilepsy drug development - Investing.com
Ovid Therapeutics raises $60 million to expand drug development - Investing.com
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Ovid Therapeutics (NASDAQ: OVID) raises $60.0 million to fund epilepsy and KCC2 pipeline - Stock Titan
Ovid Therapeutics announces pricing of $60 million private placement - marketscreener.com
Ovid Therapeutics (OVID) Shares Surge on Positive Drug Results a - GuruFocus
Ovid Therapeutics Shares Surge Over 40% on Positive OV329 Drug Results - Intellectia AI
Ovid Therapeutics (OVID) Secures $60M in PIPE Financing - GuruFocus
Ovid Therapeutics (OVID) to Launch Phase 1 Trial for Novel Drug OV4071 - GuruFocus
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms - Quiver Quantitative
Ovid funds new epilepsy and dementia trials through 2028 - Stock Titan
Ovid raises $60M to develop OV329 for tuberous sclerosis and infantile spasms - Stock Titan
Growth Recap: Does Ovid Therapeutics Inc have declining or rising EPS2026 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Breakthrough in new drug development boosts market confidence: Ovid Therapeutics Inc. (NASDAQ: OVID) shares surged 26.4% in pre-market trading today after the company announced positive safety data for its experimental epilepsy drug OV935/TAK-935. - Bitget
Financial Data Highlights: Ovid Therapeutics Inc. (NASDAQ: OVID) reported in its latest financial statement that as of December 31, 2025, the company held a total of $90.4 million in cash, cash equivalents, and marketable securities. - Bitget
Ovid Therapeutics (OVID) Receives a Buy from B. Riley Securities - The Globe and Mail
Aug Sectors: Will Ovid Therapeutics Inc announce a stock splitPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Market Trends: Does Ovid Therapeutics Inc have declining or rising EPS2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Ovid Therapeutics Gains Attention Amidst Market Fluctuations - StocksToTrade
OVID Therapeutics Faces Market Volatility Amid Recent Developments - timothysykes.com
Shorts Report: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Support Test: Is Ovid Therapeutics Inc being accumulated by smart moneyIPO Watch & High Return Trade Guides - baoquankhu1.vn
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
OVID Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):